Boyle, JG, et al., Clinical Science (2018) 132 1699–1709
学术发表
| 标题 | 发表场所 | 类型 | 时间 |
|---|---|---|---|
| ASC30, an Oral GLP-1R Biased Small Molecule Agonist Demonstrated Superior Weigh Loss in Participants with Obesity: A 28-Day Multiple Ascending Dose Study | 第61届欧洲糖尿病研究协会 （EASD 2025） | 简短口头报告 | 9/2025 |
| ASC47, An Adipose-Targeted, Muscle-Preserving Weight Loss Drug Candidate For Obesity, Demonstrated Significant Weight Loss And Preserved Muscle In DIO Mice | 第32届欧洲肥胖症大会 （ECO 2025） | 口头报告 | 5/2025 |
| ASC47, a Muscle-Preserving Weight Loss Drug Candidate in Healthy Participants: A First-in-human Single Ascending Dose Study | 第32届欧洲肥胖症大会 （ECO 2025） | 引导型海报 | 5/2025 |
| ASC30, an Oral GLP-1R Biased Small Molecule Agonist in Participants with Obesity—A First-in-Human Single Ascending Dose Study | 美国糖尿病协会第85届科学会议 （ADA 2025） | 海报 | 6/2025 |
| ASC47, a Muscle-Preserving Weight Loss Drug Candidate for Obesity, in Combination with Semaglutide, Demonstrated Superior Weight Loss to Semaglutide Monotherapy in a Preclinical Model | 美国糖尿病协会第85届科学会议 （ADA 2025） | 海报 | 海报 |
© 2018 Ascletis Pharma Inc. All Rights Reserved
浙公网安备 33010802003344号
浙ICP备11050387号-1
